Omeros Corp (OMER) — 10-Q Filings

10-Q Filings (6)

• Omeros Narrows Losses, Secures Major Novo Nordisk Deal for Zaltenibart — Nov 13, 2025 Risk: high
  Omeros Corporation reported a net loss of $30.917 million for the three months ended September 30, 2025, a slight improvement from the $32.232 million net loss
• Omeros Narrows Losses, Narsoplimab FDA Decision Pushed to December — Aug 14, 2025 Risk: high
  Omeros Corporation reported a net loss of $25.4 million for the three months ended June 30, 2025, a significant improvement from the $56.0 million net loss in t
• Omeros Corp. Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Omeros Corp. filed its 10-Q for the quarter ending March 31, 2025. The filing details financial performance and operational updates for the period. Specific fin
• Omeros Corp. Files Q3 2024 10-Q Report — Nov 13, 2024 Risk: medium
  Omeros Corp. reported its Q3 2024 results, with the filing dated November 13, 2024. The company's fiscal year ends on December 31st. Key financial data and oper
• Omeros Corp. Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Omeros Corp. reported its Q2 2024 results for the period ending June 30, 2024. The company's financial filings indicate ongoing operations and stock option acti
• Omeros Corp Files 10-Q for Q1 2024 — May 15, 2024 Risk: medium
  OMEROS CORP (OMER) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Omeros Corp reported Q1 2024 results with EPS of $0.01. The company's 2026 Note

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX